Atika Capital Management LLC Decreases Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Atika Capital Management LLC lessened its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 21.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 57,100 shares of the medical equipment provider’s stock after selling 15,900 shares during the quarter. Atika Capital Management LLC’s holdings in Lantheus were worth $5,108,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in LNTH. Geode Capital Management LLC increased its holdings in Lantheus by 2.0% in the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after buying an additional 32,551 shares in the last quarter. Reinhart Partners LLC. increased its stake in Lantheus by 9.9% in the 4th quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider’s stock valued at $122,280,000 after purchasing an additional 123,282 shares in the last quarter. Swedbank AB raised its holdings in Lantheus by 53.3% during the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock worth $99,054,000 after purchasing an additional 385,000 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Lantheus during the fourth quarter worth $36,183,000. Finally, Boston Partners grew its holdings in Lantheus by 57.5% in the fourth quarter. Boston Partners now owns 400,797 shares of the medical equipment provider’s stock valued at $36,201,000 after purchasing an additional 146,268 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Buying and Selling

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 64,109 shares of company stock valued at $6,110,806. Insiders own 2.00% of the company’s stock.

Analyst Ratings Changes

LNTH has been the topic of several recent research reports. Truist Financial boosted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. B. Riley lowered their price target on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. The Goldman Sachs Group began coverage on Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. Finally, JMP Securities reiterated a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $129.43.

Lantheus Stock Performance

LNTH stock opened at $90.92 on Friday. Lantheus Holdings, Inc. has a one year low of $58.46 and a one year high of $126.89. The stock has a market capitalization of $6.23 billion, a P/E ratio of 15.13 and a beta of 0.38. The company has a 50 day moving average price of $93.31 and a two-hundred day moving average price of $96.12.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The business had revenue of $391.11 million for the quarter, compared to analysts’ expectations of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Research analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.